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Thyroid cancer is the most common endocrine malignancy. Although most thyroid cancer patients are successfully treated and have 
an excellent prognosis, a percentage of these patients will develop aggressive disease and, eventually, progress to anaplastic thyroid 
cancer. Since most patients with this type of aggressive thyroid carcinoma will die from the disease, new treatment strategies are ur-
gently needed. Tumor cells live in a complex and dynamic tumor microenvironment composed of different types of stromal cells. 
Cancer-associated fibroblasts (CAFs) are one of the most important cell components in the tumor microenvironment of most solid 
tumors, including thyroid cancer. CAFs originate mainly from mesenchymal cells and resident fibroblasts that are activated and re-
programmed in response to paracrine factors and cytokines produced and released by tumor cells. Upon reprogramming, which is 
distinguished by the expression of different marker proteins, CAFs synthesize and secret soluble factors. The secretome of CAFs di-
rectly impacts different functions of tumor cells. This bi-directional interplay between CAFs and tumor cells within the tumor micro-
environment ends up fostering tumor cancer progression. CAFs are therefore key regulators of tumor progression and represent an 
under-explored therapeutic target in thyroid cancer. 
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INTRODUCTION
Thyroid cancer is relatively rare, representing approximately 
3% of all new cancer cases in the United States [1]. It is, how-
ever, the most common cancer in the endocrine system, and it 
has had the fastest growing incidence of all cancers over the last 
decades [2]. Among malignant tumors affecting women, its in-
cidence ranks fifth worldwide [3]. In the United States, about 
52,900 new cases of thyroid cancer are expected to be diag-
nosed in 2020 [1].
While alterations on some genes and pathways have been de-
scribed to be associated with the different forms of thyroid can-
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cer [4,5], the most recent evidence indicates that the develop-
ment and progression of cancer depend not only on genetic 
characteristics but also on the interaction of tumor cells and 
their surrounding microenvironment [6,7]. This tumor microen-
vironment (TME) is an active and dynamic component influ-
encing cancer cell behavior, disease progression, and response 
to therapy in many different types of neoplasia. The TME com-
prises a variety of non-epithelial cells (or stromal cells). Fibro-
blasts are one of the main cell components of the TME [8-11].
Although fibroblasts were first described at the end of the 
nineteenth century [12], their role in tumor development has 
only recently begun to be uncovered [6]. Normal fibroblasts 
play an important part in tissue homeostasis and wound repair 
by secreting extracellular matrix (ECM) components. In non-tu-
mor tissues they are generally quiescent. However, upon tissue 
damage, fibroblasts are activated to proliferate and increase 
their synthetic and metabolic activity. Activated fibroblasts se-
crete higher levels of ECM components to favor wound closure 
and scar formation [13,14]. Once the wound is repaired, most of 
these activated fibroblasts undergo apoptosis and their number 
decreases [15,16]. In contrast, tumors have been considered 
“wounds that do not heal” because the wound healing response 
is not self-limited and the number of activated fibroblasts is not 
decreased, as in normal wound repair [17]. Instead, fibroblasts 
in tumors, called cancer-associated fibroblasts (CAFs), are key 
players in tumor development [13]. 
Although studies analyzing the contribution of the compo-
nents of the TME, particularly CAFs, in thyroid cancer progres-
sion have been limited, the thyroid TME has become an evolv-
ing field. In this review we summarize the current knowledge 
about the origin and markers of CAFs in thyroid cancer. We fo-
cus specifically on the recent progress in understanding how 
CAFs drive thyroid cancer development and progression, from 
the standpoint of tumor-stroma interactions. We will also dis-
cuss CAFs as a promising therapeutic target in thyroid cancer. 
THYROID CANCER
Epidemiology and molecular pathogenesis
Thyroid carcinomas are classified as follicular-derived or C-
cell-derived, according to their cell of origin. The majority of 
thyroid cancers originate from follicular cells, constituting ap-
proximately 95% of all cases. Follicular-derived thyroid malig-
nancies are subdivided into differentiated thyroid cancer (DTC), 
poorly differentiated thyroid cancer (PDTC), and anaplastic 
thyroid cancer (ATC) [4,5]. DTC includes papillary thyroid can-
cer (PTC) and follicular thyroid cancer (FTC). PTC is the most 
frequent type of thyroid cancer and is found in more than 80% 
of cases. It tends to grow slowly and spreads first to local lymph 
nodes [5,18]. FTC is the second most frequent and represents 
10% to 15% of thyroid cancer cases. As with PTC, FTC can 
grow into lymph nodes in the neck. However, FTC is more like-
ly than PTC to grow into blood vessels and spread to distant ar-
eas, particularly lungs and bones [19,20]. Although PDTC (1% 
to 15%) and ATC (<1%) are uncommon tumors, they constitute 
a more aggressive follicular-derived thyroid carcinoma [21-23]. 
Parafollicular C cell-derived thyroid cancer, which constitutes 
only a small fraction of thyroid cancer (approximately 2% to 
5%), is classified as medullary thyroid cancer (MTC) and has 
distinct biological characteristics [24].
DNA sequencing studies have provided unique insights into 
the genetic basis for most thyroid cancers. The main oncogenic 
alterations of thyroid cancer occur in genes involved in mito-
gen-activated protein kinase (MAPK) and phosphatidylinositol 
3 kinase (PI3K) signaling pathways, such as BRAF, RAS, and 
RET [25,26]. The BRAFV600E mutation is the most frequent ge-
netic mutation in PTC with a prevalence of approximately 60% 
[4,18]. For FTC, point mutations in RAS genes (mainly NRAS 
and HRAS) are the most frequent, found in 40% to 50% of the 
cases [25]. Activating mutations in the RET proto-oncogene ac-
count for most cases of MTC [24]. Other genetic alterations are 
also found in thyroid cancer, including loss of tumor protein 53 
(TP53) and activating mutations in telomerase reverse transcrip-
tase (TERT) promoter in undifferentiated thyroid cancer [21, 
23,27].
Most patients with DTC have good rates of long-term surviv-
al. Standard treatment involves surgery, radioactive iodine, and 
thyroid hormone therapy [28]. The 5-year survival rate is ap-
proximately 98% [1]. A small percentage of DTCs, however, 
may manifest aggressive behavior that cannot be controlled by 
conventional therapy. Moreover, ATC is one of the most aggres-
sive and lethal human malignancies, with a short median time 
of survival (3 to 6 months). Standard therapy was not effective 
in some DTC and ATC patients. Therefore, there is an urgent 
need to identify new biological targets that can be translated 
into novel clinical approaches. 
THE TUMOR MICROENVIRONMENT
The effects of oncogenic transformation of epithelial tumor cells 
on cancer progression have been well established. In 2000, Ha-
nahan and Weinberg [29] proposed a list of six capabilities ac-
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quired by cancer cells during the process of malignant transfor-
mation. These six hallmarks of cancer consisted of uncontrolled 
proliferation, insensitivity to anti-growth signals, evasion of 
apoptosis, unlimited replicative potential, acquired capabilities 
in tissue invasion and metastasis, and sustained angiogenesis 
[29]. However, at that time, the heterogeneous and structurally 
complex nature of tumors was largely unexplored. More recent-
ly, the tumor hallmarks were updated to include TME factors 
that are required for malignant transformation [6,7]. Cancer 
cells themselves produce stimulatory factors that recruit and ac-
tivate numerous normal stromal cell types from the neighboring 
tissues as well from the circulation. Interactions between neo-
plastic cancer cells and their supporting stroma create the TME, 
which profoundly shapes cancer progression [30]. As an exam-
ple, pancreatic stellate cells (PSCs) have been reported to play a 
crucial role in the pathogenesis of pancreatic ductal adenocarci-
noma (PDAC). PSCs represent the main cell type causing the 
desmoplastic reaction, which constitutes a dramatic increase in 
connective tissue or stromal cells that surround and infiltrate the 
tumor. The desmoplastic stroma contributes to tumor growth, 
angiogenesis, invasion, and therapeutic resistance in PDAC 
[31]. Thus, studies over the past two decades have revealed that 
the TME is an equally important hallmark of tumor behavior 
[7]. The TME is composed of different cellular populations, 
such as fibroblasts, immune and endothelial cells, among oth-
ers. Fibroblasts in human tumors, also referred to as CAFs, play 
a key role in cancer development and progression in a variety of 
human tumors [8-10], including thyroid cancer.
THYROID CANCER-ASSOCIATED 
FIBROBLASTS
Recruitment and activation of fibroblasts in thyroid 
cancer
Fibroblasts are the major cellular components of the TME. In 
healthy tissues, fibroblasts are quiescent, but in the TME, they 
are reprogrammed by the tumor to acquire tumor supporting 
phenotypes. Fibroblasts can be stimulated by a variety of onco-
genic signals to acquire an activated state, also referred to as 
myofibroblasts or CAFs. Compared with quiescent fibroblasts, 
CAFs are distinguished by their morphology, their metabolic, 
synthetic, and secretory phenotypes, as well as their enhanced 
proliferative and migratory properties and ECM production [8-
10,32]. In contrast to quiescent fibroblasts, CAFs are larger, 
with more cytoplasm branches. Several protein markers are 
used to detect CAFs, including of α-smooth muscle actin 
(α-SMA), platelet-derived growth factor receptor (PDGFR)-α/β, 
fibroblast activation protein (FAP), vimentin, and neuron glial 
antigen (NG2). However, most of these markers are not unique 
to CAFs [9], making their identification challenging in some 
situations. 
What is known about the origin of CAFs? 
Numerous studies suggest that CAFs represent a heterogeneous 
component of the stroma and originate from multiple types of 
cells. A large number of them derive from mesenchymal stem 
cells and host tissue fibroblasts (pre-existing resident fibro-
blasts), which proliferate and expand locally after stimulation 
caused by cancer-derived growth factors. In addition, oncogenic 
signals produced by tumor cells may recruit fibroblasts to the 
tumor site from a distant source [8,9].
What is known about the origin of thyroid CAFs? 
CAFs have been found to be abnormally increased in thyroid 
carcinomas as compared to normal thyroid tissue. The majority 
of studies investigating CAFs in human thyroid cancer correlate 
the expression of CAF-related proteins with clinical and patho-
logical features. In a study performed in a small sample group 
of patients with PTC, the presence of CAFs (defined by α-SMA 
staining) was associated with cervical lymph node metastasis 
[33]. In another study, the expression levels of different CAF-
related proteins in human PTC was studied by using tissue mi-
croarrays, finding differences according to histologic subtypes 
and the presence of BRAFV600E mutation. Interestingly, PTCs 
with the BRAFV600E mutation exhibited high expression of some 
CAF-related proteins, such as FAP-α. This study also revealed 
that stromal positivity for PDGFR-β was associated with shorter 
overall survival in PTC [34]. In a more recent study, the pres-
ence of CAFs was investigated using immunostaining in human 
thyroid cancer. Higher levels of α-SMA-positive areas were 
found preferentially localized at the tumor invasive front, in 
PTC and ATC. However, these studies did not find a specific or 
clear association between CAFs and a particular type of thyroid 
carcinoma [35]. Conversely, a very rare or absent infiltration of 
CAFs was described by α-SMA immunostaining in a study per-
formed on patients with ATC [36]. Interestingly, a PTC murine 
model of oncogenic BRAFV600E activation in thyroid follicular 
cells showed increased fibroblast infiltration in thyroid cancer 
compared to normal thyroid tissue, in agreement with most ob-
servations in human tissue [37]. A higher density of α-SMA+ fi-
broblasts was also found in a mouse model of PTC where thy-
roid-specific expression of oncogenic BRAF is activated and 
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Pten is lost (BRAFV600E/Pten−/−/TPO-Cre) [38]. Thus, these stud-
ies demonstrate recruitment and infiltration of CAFs into the 
TME in different types of thyroid carcinomas.
Once CAFs are accumulated in the TME, evidence suggests 
that they may subsequently continue to be attracted and/or acti-
vated in response to paracrine factors released from the neigh-
boring tumor cells. For example, platelet-derived growth factor 
(PDGF), interleukin-6 (IL-6), reactive oxygen species (ROS), 
and transforming growth factor-β (TGF-β), among others, are 
key regulators of fibroblast recruitment and activation [8-11]. 
How are thyroid CAFs generated? 
It has been established that interaction between cancer cells and 
fibroblasts can promote the CAF phenotype in diverse tumor 
types. Unfortunately, the biology of tumor–stroma crosstalk in 
human thyroid cancer is largely unexplored. In a study per-
formed on patients with PTC, a significant correlation was 
found between higher TGF-β1 in cancer cells and increased 
α-SMA levels in surrounding fibroblasts [39]. To recapitulate 
the effects of tumor cell secretome on stromal cells, our labora-
tory utilized in vitro co-cultures of human thyroid cancer and 
human fibroblast cell lines. We found that thyroid cancer cell-
derived conditioned media (CM) reprogramed the thyroid fibro-
blast phenotype (Fig. 1) [40]. As mentioned before, CAFs are 
more proliferative than quiescent fibroblasts. Indeed, the num-
ber of human fibroblasts was significantly increased by treat-
ment with thyroid cancer cell-derived CM [40]. Reprogram-
ming fibroblasts into CAFs also involves alterations in their 
phenotype. We also demonstrated that thyroid cancer cell-de-
rived CM induced up-regulation of CAF markers such as 
PDGFR-β, α-SMA, and vimentin in human thyroid fibroblasts 
[40]. It has been demonstrated that, when transformed, CAFs 
show important metabolic alterations. In fact, glucose transport-
er 1 (GLUT-1) was markedly increased in human thyroid fibro-
blasts when cultured with thyroid cancer cell-derived CM (Fig. 
1) [40]. Interestingly, we found that in addition to IL-6 and 
ROS, thyroid cancer cells secreted high amounts of PDGF into 
the media. All these soluble factors could serve as causative 
molecules that activate fibroblasts [40]. In line with our find-
ings, Jolly et al. [38] reported that CM collected from thyroid 
cancer cells generated from BRAFV600E/Pten−/−/TPO-Cre mice 
significantly increased proliferation and migration of murine 
CAFs. Collectively, these data suggest that tumor-derived solu-
ble factors can induce a CAF phenotype in thyroid carcinoma 
(Fig. 1). Nonetheless, many key questions still remain unsolved. 
For example, in addition to the paracrine signals generated by 
Fig. 1. Activation of thyroid fibroblasts. Cancer cells produce cytokines, chemokines, and growth factors to stimulate the transformation of 
quiescent or resting fibroblasts into activated cancer-associated fibroblasts (CAFs). Reprogramming of CAFs involves the increase in the 
levels of α-smooth muscle actin (α-SMA), vimentin, and platelet-derived growth factor receptor β (PDGFR-β), among other possible CSF 
markers. In addition, activated fibroblasts increase their proliferative properties and reprogram their secretory and metabolic phenotypes. 
Graphic created using BioRender. GLUT-1, glucose transporter 1.
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tumor cells, can cues released by other cells in the TME also 
contribute to fibroblast activation? Further studies are required 
to explore other TME-derived factors in thyroid cancer cells as 
well as the pathways involved in phenotypic reprogramming of 
human thyroid fibroblasts.
Crosstalk between tumor cells and CAFs: tumor-
stimulatory effects of CAFs in thyroid cancer
As tumors grow, CAF cell numbers increase and accumulate. 
Once CAFs are reprogrammed, they influence most of the hall-
mark capabilities of cancer cells, playing key roles in the pro-
cess of cancer development and progression through a variety 
of mechanisms. CAFs can exert their tumorigenic functions di-
rectly by cell–cell contact and indirectly by utilizing secreted 
factors. The array of functions and the mechanisms by which 
CAFs promote tumor progression are outside the scope of this 
review, but have been discussed in detail elsewhere [8-11,32]. 
However, it is important to point it out that CAFs are a consid-
erable source of multiple secreted factors. So, we will focus on 
the CAF secretome and how it influences cancer cell behavior 
to support malignant thyroid tumor growth. 
What are the functions of CAFs in thyroid carcinogenesis? 
Only a few studies have provided direct evidence of the pro-tu-
morigenic role of CAFs in thyroid cancer. Using an in vivo sub-
cutaneous model, Saitoh et al. [41] demonstrated the crucial role 
of the interaction between thyroid tumor cells and skin fibro-
blasts to promote the growth of tumors, in rats. According to the 
model, co-injection of tumorigenic Fisher rat thyroid follicular 
cells (FRTL-Tc) mixed with skin fibroblasts resulted in subcuta-
neous tumors larger than those derived from FRTL-Tc cells 
alone. Interestingly, the authors reported that fibroblasts en-
hance the growth of thyroid carcinoma by secreting soluble fac-
tors, although they did not identify any of them [41]. Another 
important contribution in understanding the functional effects of 
soluble factors released by CAFs on thyroid tumor progression 
has recently been provided by our laboratory. By using in vitro 
co-cultures, we have found that thyroid cancer cells treated with 
CAFs CM showed increased proliferation and invasion. In addi-
tion, we determined that soluble factors secreted by CAFs were 
able to activate epithelial-to-mesenchymal transition (EMT) in 
thyroid cancer cells. Classical mitogens for epithelial cancer 
cells, such as IL-6, were highly expressed and secreted by CAFs. 
We also found that ROS are abundantly produced by pro-tumor-
igenic CAFs and secreted into the media [40]. Secretion of IL-6 
and ROS by CAFs, among other soluble factors, are believed to 
promote thyroid tumor aggressiveness. 
Another distinctive feature of CAFs is their ability to produce 
and deposit ECM. Alterations in the composition and cross-
linking of the ECM change the stiffness of the tissue, thereby 
critically regulating tumorigenesis. The main constituents of the 
ECM are collagens [9]. Twenty-eight different collagens have 
been identified [42], and their assembly is highly regulated by 
the activity of enzymes, such as lysyl oxidase (LOX) [43]. In-
terestingly, LOX, an enzyme responsible for collagen cross-
linking, was found to be highly expressed in aggressive thyroid 
carcinomas as compared to DTCs and normal thyroid tissues 
[35,44]. In addition, LOX inhibition significantly reduced the 
migration and invasion of ATC cell lines [44]. A recent study re-
ported that BRAF-mutant tumors with high LOX expression 
were associated with more aggressive disease in thyroid cancer 
[45]. Consistent with these observations, in thyroid tumors from 
BRAFV600E murine models LOX expression levels were signifi-
cantly higher than in normal tissue [38]. However, our current 
understanding of LOX and how it interacts with CAFs in thy-
roid cancer is still primitive, and more research is needed in or-
der to design potential novel anti-tumor strategies based on 
LOX targeting for thyroid cancer.
Together, thyroid CAFs participate in a dynamic and interactive 
interplay with thyroid neoplastic cells. By secreting soluble fac-
tors (ROS, PDGF, and IL-6) thyroid tumor cells activate quies-
cent fibroblasts into CAFs. After activation, CAFs initiate the se-
cretion of soluble factors and increase the ECM production, inter-
acting with thyroid cells to foster malignant thyroid tumor growth 
by promoting cell proliferation, invasion, and EMT (Fig. 2).
Implications of targeting thyroid CAFs: therapeutic 
perspectives
Thyroid carcinoma, the most common form of endocrine malig-
nancy, has an increasing incidence worldwide. While DTCs 
usually have a good prognosis, ATC is one of the most lethal 
solid tumors known. Conventional treatments of advanced thy-
roid cancer remain very challenging, and additional research is 
needed to find new treatment strategies to improve patient out-
come.
Accumulating evidence indicates that CAFs exert pro-tumor-
igenic functions, making the different mechanisms that CAFs 
use to stimulate cancer cells exceptional therapeutic targets for 
cancer treatment [46]. Most strategies to manipulate CAFs to 
treat cancer focus on interfering with activation of CAFs or in-
hibiting CAF functions. Several combinatorial strategies target-
ing TGF-β, which regulates the activation of CAFs, are current-
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ly being tested in clinical trials. For example, galunisertib, a 
TGF-β receptor inhibitor, resulted in improved survival of pa-
tients with pancreatic cancer [47]. Inhibiting oncogenic signals 
secreted by CAFs by inhibitors or antibodies represents another 
attractive therapeutic strategy. Inhibitors of IL-6 are currently in 
use in different clinical trials and may be useful in combination 
therapies to treat cancer [48]. These observations highlight the 
potential of a wide range of therapeutic strategies targeting 
CAFs. 
CONCLUSIONS
The role of the TME, particularly CAFs, in the development of 
thyroid cancer has long been underestimated. There is now 
more evidence clearly suggesting that interactions between 
CAFs and cancer cells are involved in thyroid cancer progres-
sion. Indeed, some of the mechanisms that these cells of the 
TME use to promote thyroid tumor progression have recently 
been identified. These findings have made CAFs a promising 
new therapeutic target in thyroid cancer. Even so, numerous un-
answered questions remain regarding CAFs in the thyroid can-
cer field. We believe that better understanding of thyroid CAFs’ 
activation and function, as well the relationship between CAFs 
and thyroid cancer cells, is needed to design improved anti-can-
cer therapies in the future. These novel strategies can then be 
combined to enhance thyroid cancer patient outcome.
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